{"created":"2023-05-15T14:34:53.998740+00:00","id":45119,"links":{},"metadata":{"_buckets":{"deposit":"31e3ca8b-0da5-4ab3-be36-5cc717953767"},"_deposit":{"created_by":1,"id":"45119","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"45119"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00045119","sets":["1"]},"author_link":["448065","448063","448069","448070","448067","448071","448066","448064","448068","448062"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2007-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"162","bibliographicPageStart":"154","bibliographicVolumeNumber":"25","bibliographic_titles":[{"bibliographic_title":"Cancer Investigation"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives: 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has been shown to be useful in diagnosis and staging of pancreatic cancer. However, the prognostic value of FDG-PET remains controversial. The aim of this study was to evaluate relations between the factors suggested to be related to the FDG accumulation in tumor tissue, such as glucose transporter-1 (GLUT-1), hexokinase type-II (HK-II), proliferating cell nuclear antigen (PCNA), and survival of pancreatic cancer patients. Methods: Histological specimen of pancreatic cancer obtained from seventy-four consecutive patients were evaluated for the expression of GLUT-1, HK-II, and PCNA by visual analysis of immunohistochemical staining of paraffin sections from the tumor specimens using anti-GLUT-1, anti-HK-II, and anti-PCNA antibody, respectively. The percentages of cells strongly expressing GLUT-1, HK-II and PCNA were scored on a 5-point scale (1 = 0-20 percent, 2 = 20-40 percent, 3 = 40-60 percent, 4 = 60-80 percent, 5 = 80-100 percent). After initial treatment, each patient was followed-up and survival time was recorded. Median survival curves of the patients with different levels of GLUT-1, HK-II, and PCNA expression were evaluated using the Kaplan-Meier method. Statistical significance of the  differences in survival was calculated with the log rank test. Results: Median survival of examined patients showed no relation with the levels of GLUT-1 expression, while patients with low expression of HK-II (HK-II index < 3) had significantly shorter survival than those with higher expression of HK-II (HK-II index  3) (6.5 +- 4.1 versus 12.9 +- 22.4 months, respectively, p < 0.05). Median survival of examined patients also showed significant relations with the levels of PCNA expression. Patients with low expression of PCNA (PCNA index < 4) had significantly longer survival than those with higher expression of PCNA (PCNA index  4) (11.9 +- 20.1 versus, 5.8 +- 10.8 months, respectively, p < 0.01): Conclusions: Our results showed that the expression of GLUT-1 had no prognostic value in the examined patients with pancreatic cancer. On the other hand, high levels of HK-II expression and low levels of PCNA expression may allow accurate identification of the patient with longer survival who may benefit from intensive anticancer treatment.","subitem_description_type":"Abstract"}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0735-7907","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Lyshchik, Andrej"}],"nameIdentifiers":[{"nameIdentifier":"448062","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"448063","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hara, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"448064","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakamoto, Yuji"}],"nameIdentifiers":[{"nameIdentifier":"448065","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fujimoto, Koji"}],"nameIdentifiers":[{"nameIdentifier":"448066","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Doi, Ryuichiro"}],"nameIdentifiers":[{"nameIdentifier":"448067","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Imamura, Masayuki"}],"nameIdentifiers":[{"nameIdentifier":"448068","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saga, Tsuneo"}],"nameIdentifiers":[{"nameIdentifier":"448069","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Togashi, Kaori"}],"nameIdentifiers":[{"nameIdentifier":"448070","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐賀 恒夫","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"448071","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Expression of Glucose Transporter-1, Hexokinase-II, Proliferating Cell Nuclear Antigen and Survival of Patients with Pancreatic Cancer.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Expression of Glucose Transporter-1, Hexokinase-II, Proliferating Cell Nuclear Antigen and Survival of Patients with Pancreatic Cancer."}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2008-03-21"},"publish_date":"2008-03-21","publish_status":"0","recid":"45119","relation_version_is_last":true,"title":["Expression of Glucose Transporter-1, Hexokinase-II, Proliferating Cell Nuclear Antigen and Survival of Patients with Pancreatic Cancer."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-16T00:07:27.690276+00:00"}